Kevin M. Brennan's most recent trade in Xilio Therapeutics Inc was a trade of 95,221 Stock Option (right to buy) done . Disclosure was reported to the exchange on Dec. 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2025 | 95,221 | 95,221 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 5,000 | 8,197 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2025 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale of securities on an exchange or to another person at price $ 0.64 per share. | 31 Dec 2025 | 1,826 | 6,371 | - | 0.6 | 1,174 | Common Stock |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 131,700 | 131,700 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 55,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 25,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Nov 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 5,000 | 5,000 | - | - | Common Stock | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 5,000 | 15,000 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Sale of securities on an exchange or to another person at price $ 0.98 per share. | 01 Jan 2025 | 1,803 | 3,197 | - | 1.0 | 1,774 | Common stock |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 26,000 | 26,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Kevin Brennan M. | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Xilio Therapeutics Inc | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 55,000 | 55,000 | - | - | Stock Option (right to buy) |